Deal notes
Closing has not been confirmed in the reviewed sources. This record does not establish that funding was received.
Transaction overview
01Autonomix Medical, Inc. announced a $4.9M warrant exercise / inducement at $5.75 per warrant exercised. Maxim Group LLC acted as warrant inducement agent for the financing.
- Financing type
- Warrant Exercise / Inducement
- Announcement date
- Aug 24, 2026
- Pricing date
- Aug 24, 2026
- Closing date
- —
- Filing date
- Aug 26, 2026
- Status
- Priced
- Market cap before announcement
- $2.9M
- Prior closing price
- $5.27
- Raise as % of market cap
- 171%
Market data · FMP
- Historical market cap
- $2,865,219.95
- Market date
- Aug 21, 2026
- Closing price
- $5.27
- Latest reported shares outstanding
- —
- Latest reported float shares
- —
- Share-data date
- —
Market cap and closing price are from FMP for the date shown. Shares are FMP’s latest available snapshot, dated separately. Updated Sep 30, 2026.
Financial Modeling Prep ↗Financing terms
02Warrant exercise / inducement
- Warrants exercised
- 857,462
- Original exercise price
- $5.75
- Exercise price paid
- $5.75
- Cash proceeds
- $4.9M
Investor warrants
- Warrant shares
- 1,071,826
- Cash exercise price
- $6.25
- Term
- Series E-1: 535,913; Series E-2: 535,913. Both five years from issuance; immediately exercisable. E-2 alone has the disclosed Black Scholes redemption right.
- Initial exercisability
- —
- Beneficial ownership limits
- The Holder of a New Warrant may not exercise any such warrant to the extent that such exercise would result in the number of shares of common stock beneficially owned by such Holder and its affiliates exceeding 4.99% or 9.99% (at the election of the Holder) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the Holder’s election not to exceed 9.99% (the “Beneficial Ownership Limitation”).
View disclosed legal provisions
Cashless exercise: The New Warrants may only be exercised on a cashless basis if, commencing six months after issuance, there is no effective registration statement registering, or the prospectus contained therein is not available for, the resale of the shares of common stock underlying the New Warrants by the Holder.
Anti-dilution: The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate proportional adjustment in the event of share dividends, share splits, reorganizations or similar events affecting the Company’s common stock and the exercise price.
Fees & transaction economics
03- Placement agent / underwriting fee
- 7%
- Agent fee amount
- $343,000
- Management fee
- —
- Other offering expenses (estimated)
- —
- Net proceeds (estimated)
- —
- Net proceeds as % of gross
- —
Fee amounts reflect disclosed inputs. Unknown expense components are not assumed to be zero.
Maxim fee 7% of exercised-warrant cash proceeds; reasonable expenses reimbursable up to $15,000. New E-2 warrants have specified Black Scholes redemption rights; E-1 warrants do not.
Transaction participants
04Source documents
05SEC filings, exhibits and attributed market data. The report separates disclosed facts, calculated metrics, and unknown terms.
Filing evidence & original calculations
4900000
gross proceeds from the exercise of the warrants are expected to be approximately $4.9 millionOriginal source ↗
7
cash fee equal to 7.0% of the total proceeds received by the Company from the exercise of the Existing WarrantsOriginal source ↗
5.75
at the original exercise price of $5.75 per Warrant ShareOriginal source ↗
1071826
Series E-1 warrants to purchase an aggregate of 535,913 shares of the Company’s common stock, and unregistered Series E-2 warrants to purchase an aggregate of 535,913 sharesOriginal source ↗
Series E-1: 535,913; Series E-2: 535,913. Both five years from issuance; immediately exercisable. E-2 alone has the disclosed Black Scholes redemption right.
The Holder of a New Series E-1 Warrant will not have such a Black Scholes redemption right.Original source ↗
The New Warrants may only be exercised on a cashless basis if, commencing six months after issuance, there is no effective registration statement registering, or the prospectus contained therein is not available for, the resale of the shares of common stock underlying the New Warrants by the Holder.
The New Warrants may only be exercised on a cashless basis if, commencing six months after issuance, there is no effective registration statement registering, or the prospectus contained therein is not available for, the resale of the shares of common stock underlying the New Warrants by the Holder.Original source ↗
The Holder of a New Warrant may not exercise any such warrant to the extent that such exercise would result in the number of shares of common stock beneficially owned by such Holder and its affiliates exceeding 4.99% or 9.99% (at the election of the Holder) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the Holder’s election not to exceed 9.99% (the “Beneficial Ownership Limitation”).
The Holder of a New Warrant may not exercise any such warrant to the extent that such exercise would result in the number of shares of common stock beneficially owned by such Holder and its affiliates exceeding 4.99% or 9.99% (at the election of the Holder) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the Holder’s election not to exceed 9.99% (the “Beneficial Ownership Limitation”).Original source ↗
The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate proportional adjustment in the event of share dividends, share splits, reorganizations or similar events affecting the Company’s common stock and the exercise price.
The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate proportional adjustment in the event of share dividends, share splits, reorganizations or similar events affecting the Company’s common stock and the exercise price.Original source ↗
Maxim fee 7% of exercised-warrant cash proceeds; reasonable expenses reimbursable up to $15,000. New E-2 warrants have specified Black Scholes redemption rights; E-1 warrants do not.
to reimburse Maxim for its reasonable expenses in an amount not to exceed $15,000Original source ↗
FMP reported market cap; as of 2026-08-21.
{"provider": "FMP", "symbol": "AMIX", "date": "2026-08-21", "marketCap": 2865219.95}Original source ↗